Cyclo Therapeutics, Inc. Reports Q2 Loss, Misses Revenue Estimates
CYTH Stock | USD 0.82 0.01 1.23% |
Under 70 percent of all Cyclo Therapeutics' traders are curious in acquiring. The analysis of the overall investor sentiment regarding Cyclo Therapeutics suggests that a large number of traders are confidant. Cyclo Therapeutics' investing sentiment shows overall attitude of investors towards Cyclo Therapeutics.
Cyclo |
Cyclo Therapeutics delivered earnings and revenue surprises of -50 percent and 69.25, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock
Read at zacks.com
Cyclo Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cyclo Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cyclo Therapeutics Fundamental Analysis
We analyze Cyclo Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Cyclo Therapeutics is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Cyclo Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cyclo Therapeutics stock to make a market-neutral strategy. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics with similar companies.
Peers
Cyclo Therapeutics Related Equities
ADTX | Aditxt | 6.64 | ||||
MIST | Milestone Pharmaceuticals | 3.02 | ||||
SCPH | Scpharmaceuticals | 2.49 | ||||
ARMP | Armata Pharmaceuticals | 1.83 | ||||
SRZN | Surrozen | 1.91 | ||||
KTTA | Pasithea Therapeutics | 2.01 | ||||
CADL | Candel Therapeutics | 2.41 | ||||
MCRB | Seres Therapeutics | 3.37 | ||||
INKT | Mink Therapeutics | 5.10 | ||||
ONCY | Oncolytics Biotech | 10.23 |
Complementary Tools for Cyclo Stock analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |